Cargando…

Circulating anti-inflammatory adipokines High Molecular Weight Adiponectin and Zinc-α2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: a pilot study

BACKGROUND: Adipose tissue has been identified as an endocrine organ secreting adipokines involved in metabolic and inflammatory pathways. Adiponectin, an anti-inflammatory adipokine, is reduced in sepsis. High Molecular Weight (HMW) adiponectin, the biologically most relevant molecule, has been inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Welters, Ingeborg D, Bing, Chen, Ding, Cherlyn, Leuwer, Martin, Hall, Alison M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289554/
https://www.ncbi.nlm.nih.gov/pubmed/25580089
http://dx.doi.org/10.1186/1471-2253-14-124
_version_ 1782352127686868992
author Welters, Ingeborg D
Bing, Chen
Ding, Cherlyn
Leuwer, Martin
Hall, Alison M
author_facet Welters, Ingeborg D
Bing, Chen
Ding, Cherlyn
Leuwer, Martin
Hall, Alison M
author_sort Welters, Ingeborg D
collection PubMed
description BACKGROUND: Adipose tissue has been identified as an endocrine organ secreting adipokines involved in metabolic and inflammatory pathways. Adiponectin, an anti-inflammatory adipokine, is reduced in sepsis. High Molecular Weight (HMW) adiponectin, the biologically most relevant molecule, has been investigated very little in human sepsis. Zinc-alpha2-glycoprotein (ZAG) is a novel adipokine and its expression in adipose tissue is positively correlated with adiponectin expression. It is not yet known whether ZAG has a role in sepsis. In this study we assessed levels of HMW adiponectin and ZAG during different stages of sepsis. METHODS: A prospective observational pilot study was carried out on 21 septic patients. Serum samples were taken on day 1 and 2 post ICU admission and on day of discharge. Samples were analysed for total and HMW adiponectin, HMW/total adiponectin ratio, and ZAG. Results were correlated with clinical and metabolic data. RESULTS: There were no differences in total adiponectin, HMW adiponectin and ZAG plasma concentrations between day 1 (admission) and day 2 of the sepsis episode. Compared to admission, a significant increase in total and HMW adiponectin and ZAG was observed on the day of discharge when clinical improvement had been achieved. There was also an increase in the HMW/total adiponectin ratio at that time. CONCLUSIONS: Our data demonstrate an increase in both HMW adiponectin and total adiponectin in patients who had clinically recovered from sepsis. The increase in HMW/total adiponectin ratio with improvement of the clinical condition suggests that HMW adiponectin may have a greater role in the inflammatory process and insulin resistance seen in sepsis. In this pilot study, we have also demonstrated a significant increase in ZAG in critically ill patients temporally related to recovery from sepsis.
format Online
Article
Text
id pubmed-4289554
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42895542015-01-12 Circulating anti-inflammatory adipokines High Molecular Weight Adiponectin and Zinc-α2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: a pilot study Welters, Ingeborg D Bing, Chen Ding, Cherlyn Leuwer, Martin Hall, Alison M BMC Anesthesiol Research Article BACKGROUND: Adipose tissue has been identified as an endocrine organ secreting adipokines involved in metabolic and inflammatory pathways. Adiponectin, an anti-inflammatory adipokine, is reduced in sepsis. High Molecular Weight (HMW) adiponectin, the biologically most relevant molecule, has been investigated very little in human sepsis. Zinc-alpha2-glycoprotein (ZAG) is a novel adipokine and its expression in adipose tissue is positively correlated with adiponectin expression. It is not yet known whether ZAG has a role in sepsis. In this study we assessed levels of HMW adiponectin and ZAG during different stages of sepsis. METHODS: A prospective observational pilot study was carried out on 21 septic patients. Serum samples were taken on day 1 and 2 post ICU admission and on day of discharge. Samples were analysed for total and HMW adiponectin, HMW/total adiponectin ratio, and ZAG. Results were correlated with clinical and metabolic data. RESULTS: There were no differences in total adiponectin, HMW adiponectin and ZAG plasma concentrations between day 1 (admission) and day 2 of the sepsis episode. Compared to admission, a significant increase in total and HMW adiponectin and ZAG was observed on the day of discharge when clinical improvement had been achieved. There was also an increase in the HMW/total adiponectin ratio at that time. CONCLUSIONS: Our data demonstrate an increase in both HMW adiponectin and total adiponectin in patients who had clinically recovered from sepsis. The increase in HMW/total adiponectin ratio with improvement of the clinical condition suggests that HMW adiponectin may have a greater role in the inflammatory process and insulin resistance seen in sepsis. In this pilot study, we have also demonstrated a significant increase in ZAG in critically ill patients temporally related to recovery from sepsis. BioMed Central 2014-12-18 /pmc/articles/PMC4289554/ /pubmed/25580089 http://dx.doi.org/10.1186/1471-2253-14-124 Text en © Welters et al.; licensee BioMed Central. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Welters, Ingeborg D
Bing, Chen
Ding, Cherlyn
Leuwer, Martin
Hall, Alison M
Circulating anti-inflammatory adipokines High Molecular Weight Adiponectin and Zinc-α2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: a pilot study
title Circulating anti-inflammatory adipokines High Molecular Weight Adiponectin and Zinc-α2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: a pilot study
title_full Circulating anti-inflammatory adipokines High Molecular Weight Adiponectin and Zinc-α2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: a pilot study
title_fullStr Circulating anti-inflammatory adipokines High Molecular Weight Adiponectin and Zinc-α2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: a pilot study
title_full_unstemmed Circulating anti-inflammatory adipokines High Molecular Weight Adiponectin and Zinc-α2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: a pilot study
title_short Circulating anti-inflammatory adipokines High Molecular Weight Adiponectin and Zinc-α2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: a pilot study
title_sort circulating anti-inflammatory adipokines high molecular weight adiponectin and zinc-α2-glycoprotein (zag) are inhibited in early sepsis, but increase with clinical recovery: a pilot study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289554/
https://www.ncbi.nlm.nih.gov/pubmed/25580089
http://dx.doi.org/10.1186/1471-2253-14-124
work_keys_str_mv AT weltersingeborgd circulatingantiinflammatoryadipokineshighmolecularweightadiponectinandzinca2glycoproteinzagareinhibitedinearlysepsisbutincreasewithclinicalrecoveryapilotstudy
AT bingchen circulatingantiinflammatoryadipokineshighmolecularweightadiponectinandzinca2glycoproteinzagareinhibitedinearlysepsisbutincreasewithclinicalrecoveryapilotstudy
AT dingcherlyn circulatingantiinflammatoryadipokineshighmolecularweightadiponectinandzinca2glycoproteinzagareinhibitedinearlysepsisbutincreasewithclinicalrecoveryapilotstudy
AT leuwermartin circulatingantiinflammatoryadipokineshighmolecularweightadiponectinandzinca2glycoproteinzagareinhibitedinearlysepsisbutincreasewithclinicalrecoveryapilotstudy
AT hallalisonm circulatingantiinflammatoryadipokineshighmolecularweightadiponectinandzinca2glycoproteinzagareinhibitedinearlysepsisbutincreasewithclinicalrecoveryapilotstudy